Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,606 | 365 | 99.6% |
| Education | $20.67 | 4 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $932.97 | 62 | $0 (2024) |
| ABBVIE INC. | $793.99 | 58 | $0 (2024) |
| PFIZER INC. | $773.81 | 74 | $0 (2024) |
| GlaxoSmithKline, LLC. | $465.79 | 28 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $340.97 | 11 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $328.49 | 23 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $310.09 | 17 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $286.23 | 17 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $161.49 | 5 | $0 (2022) |
| Amgen Inc. | $151.43 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $425.06 | 26 | Almatica Pharma LLC ($81.84) |
| 2023 | $893.90 | 55 | AbbVie Inc. ($275.10) |
| 2022 | $847.84 | 58 | ABBVIE INC. ($293.21) |
| 2021 | $900.14 | 67 | PFIZER INC. ($176.22) |
| 2020 | $149.06 | 9 | PFIZER INC. ($56.29) |
| 2019 | $188.20 | 12 | Novo Nordisk Inc ($148.92) |
| 2018 | $766.14 | 47 | Novo Nordisk Inc ($175.98) |
| 2017 | $1,457 | 95 | Janssen Pharmaceuticals, Inc ($298.86) |
All Payment Transactions
369 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: ANTI-ANXIETY | ||||||
| 11/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Diabetes | ||||||
| 09/10/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.80 | General |
| Category: Diabetes | ||||||
| 09/09/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $16.43 | General |
| Category: Heart Failure and Hypertension | ||||||
| 08/27/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/08/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $14.37 | General |
| Category: Respiratory | ||||||
| 07/25/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 07/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: NEUROSCIENCE | ||||||
| 07/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.09 | General |
| Category: Diabetes | ||||||
| 06/20/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/13/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: NEUROSCIENCE | ||||||
| 05/29/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: ANTI-ANXIETY | ||||||
| 05/23/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $14.19 | General |
| Category: Cardiovascular | ||||||
| 04/16/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: NEUROSCIENCE | ||||||
| 03/27/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: Inflammation | ||||||
| 03/27/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Cardiology | ||||||
| 03/14/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $17.62 | General |
| Category: ANTI-ANXIETY | ||||||
| 03/13/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $17.57 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/08/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/26/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/22/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: Diabetes | ||||||
| 02/15/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: ANTI-ANXIETY | ||||||
| 02/05/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.33 | General |
| Category: NEUROSCIENCE | ||||||
| 01/24/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $19.12 | General |
| Category: ANTI-ANXIETY | ||||||
| 01/17/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: WATCHMAN FLX_IC | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 944 | 1,430 | $181,853 | $80,427 |
| 2022 | 28 | 1,853 | 2,392 | $186,224 | $91,791 |
| 2021 | 28 | 2,373 | 3,564 | $210,412 | $107,279 |
| 2020 | 28 | 1,996 | 2,847 | $169,372 | $74,952 |
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 312 | 639 | $63,920 | $23,299 | 36.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Facility | 2023 | 159 | 159 | $27,825 | $18,560 | 66.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 219 | 331 | $46,340 | $17,959 | 38.8% |
| 99496 | Transitional care management services for problem of high complexity | Facility | 2023 | 33 | 38 | $8,360 | $5,321 | 63.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 56 | $9,800 | $4,799 | 49.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 22 | $3,080 | $1,883 | 61.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 15 | $4,875 | $1,784 | 36.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 23 | $2,405 | $1,342 | 55.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 21 | 26 | $3,120 | $1,336 | 42.8% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Facility | 2023 | 11 | 11 | $2,365 | $1,130 | 47.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 12 | 12 | $1,440 | $707.76 | 49.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 14 | 15 | $1,920 | $562.01 | 29.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Facility | 2023 | 16 | 22 | $2,090 | $484.63 | 23.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 19 | 21 | $1,260 | $415.36 | 33.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Facility | 2023 | 11 | 12 | $888.00 | $411.07 | 46.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 13 | 13 | $2,015 | $386.77 | 19.2% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2023 | 14 | 15 | $150.00 | $46.65 | 31.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 298 | 487 | $50,340 | $22,444 | 44.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 158 | 206 | $31,577 | $14,650 | 46.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 141 | 167 | $16,700 | $7,862 | 47.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Facility | 2022 | 52 | 52 | $9,100 | $6,165 | 67.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 49 | 49 | $8,965 | $5,842 | 65.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 44 | 68 | $10,998 | $5,136 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 60 | 64 | $8,960 | $4,349 | 48.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $7,103 | $3,099 | 43.6% |
About Dr. Mark Bradshaw, M.D
Dr. Mark Bradshaw, M.D is a Family Medicine healthcare provider based in Wynne, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346355518.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Bradshaw, M.D has received a total of $5,627 in payments from pharmaceutical and medical device companies, with $425.06 received in 2024. These payments were reported across 369 transactions from 35 companies. The most common payment nature is "Food and Beverage" ($5,606).
As a Medicare-enrolled provider, Bradshaw has provided services to 7,166 Medicare beneficiaries, totaling 10,233 services with total Medicare billing of $354,449. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Wynne, AR
- Active Since 08/20/2006
- Last Updated 03/29/2012
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1346355518
Products in Payments
- ELIQUIS (Drug) $519.94
- UBRELVY (Drug) $479.27
- Ozempic (Drug) $459.95
- TRELEGY ELLIPTA (Drug) $327.87
- JARDIANCE (Drug) $287.69
- QULIPTA (Drug) $257.08
- FARXIGA (Drug) $210.70
- XARELTO (Drug) $189.93
- Tresiba (Drug) $169.71
- ENTRESTO (Drug) $161.49
- GEMTESA (Drug) $158.89
- CHANTIX (Drug) $158.48
- Victoza (Drug) $142.01
- INVOKANA (Drug) $138.56
- AREXVY (Drug) $123.74
- LOREEV XR (Drug) $121.83
- Ranexa (Drug) $100.00
- Utibron (Drug) $93.82
- LYRICA (Drug) $88.16
- TOUJEO (Drug) $85.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Wynne
Dr. Willard Burks, M.d, M.D
Family Medicine — Payments: $5,354
Dr. James Cathey, M.d, M.D
Family Medicine — Payments: $4,594
Dr. James Beaton, M.d, M.D
Family Medicine — Payments: $3,374
Sean Koch, Md, MD
Family Medicine — Payments: $3,138
Jeremiah Nugent, M.d, M.D
Family Medicine — Payments: $2,336
Mrs. Lesli Anderson, Aprn, APRN
Family Medicine — Payments: $390.90